Snapshot of innovations in R&D targeting key applications of drug delivery technologies
![](/46/pdcnewsitem/03/87/01/research%20and%20markets.jpg)
Oral Route, pulmonary, topical, implantable, injectable, transdermal and transmucosal route analysis.
Research and Markets (http://www.researchandmarkets.com/research/8cqjfl/novel) has added the "Novel Applications of Drug Delivery Technologies (TechVision)" report to their offering.
The drug delivery market has witnessed immense growth in the last decade due to the penetration of drug delivery technologies in varied applications ranging from medicine to cosmetics. Increasing presence of technology manufacturers, rise in demand for novel products to deliver drugs and a diverse portfolio of technologies from key stakeholders combined with newer licensing agreements and partnerships has resulted in a steady growth of this market.
The research study covers the market share assessment of the most common routes of drug administration that range from oral route of administration to most recent developments in transdermal drug delivery. Key market drivers and challenges section details the factors that are likely to hold key in the success of drug delivery systems across various industries apart from medicine.
The research study further details the adoption of these technologies in regions of North America, Europe and Asia-Pacific, explaining the likelihood of adoption of individual routes of administration in these regions. A number of medical and non-medical applications have been presented that also include key innovators in these segments. Finally, a number of technology management strategies and an emerging technology road map has been set forth to explore the opportunity evaluation in this market.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance